ライフサイエンスコーパス: cardiovascular events

1 ertugliflozin vs. placebo] for major adverse cardiovascular events).

2 bserved in the primary outcome (composite of cardiovascular events).

3 Results were similar for major adverse cardiovascular events.

4 ve stress that correlates with occurrence of cardiovascular events.

5 ients remain at high risk of developing late cardiovascular events.

6 ate with endothelial dysfunction and predict cardiovascular events.

7 ed in patients at low risk for major adverse cardiovascular events.

8 poprotein (LDL) cholesterol results in fewer cardiovascular events.

9 ior to placebo with respect to major adverse cardiovascular events.

10 s not been fully evaluated as a predictor of cardiovascular events.

11 and a higher risk of atherosclerosis-related cardiovascular events.

12 ere not associated with the risk of death or cardiovascular events.

13 gnificantly reduce the risk of major adverse cardiovascular events.

14 T dynamics during exercise and recovery with cardiovascular events.

15 kely to experience longer-term major adverse cardiovascular events.

16 poproteins (remnant cholesterol) can predict cardiovascular events.

17 mab would reduce the total burden of serious cardiovascular events.

18 d counterparts regarding mortality and major cardiovascular events.

19 y is associated with increased risk of major cardiovascular events.

20 oprotein(a) concentration is associated with cardiovascular events.

21 ater in men than women and are predictive of cardiovascular events.

22 needed to determine the effects of SNF472 on cardiovascular events.

23 l cardiac mechanics and an increased risk of cardiovascular events.

24 ibration for predicting 5-year major adverse cardiovascular events.

25 both primary ischemic stroke and subsequent cardiovascular events.

26 ntribution of plaque and systemic factors to cardiovascular events.

27 viduals from UK Biobank without a history of cardiovascular events.

28 are at high risk for major adverse limb and cardiovascular events.

29 ich failed to show significant reductions in cardiovascular events.

30 volume by T1 mapping and was associated with cardiovascular events.

31 nce of high-risk coronary plaque and risk of cardiovascular events.

32 ardiometabolic health and increases rates of cardiovascular events.

33 lide, with a 54% lower risk of major adverse cardiovascular events.

34 to evaluate the effect of statin therapy on cardiovascular events.

35 Incident CVD included nonfatal and fatal cardiovascular events.

36 as Mediterranean diet) and the incidence of cardiovascular events.

37 ction and impairment of cardiac function and cardiovascular events.

38 an important independent predictor of future cardiovascular events.

39 lure (HF) are at high risk for major adverse cardiovascular events.

40 ) have increased risk on future cerebro- and cardiovascular events.

41 RT was not associated with increased risk of cardiovascular events.

42 sociated with an increased risk of recurrent cardiovascular events.

43 ischemia and also be a predictor of adverse cardiovascular events.

44 TCOME demonstrated a broad risk spectrum for cardiovascular events.

45 rsus Mediterranean diet) on the incidence of cardiovascular events.

46 end point; 29 died and 33 had major adverse cardiovascular events.

47 ase regression and prevent the recurrence of cardiovascular events.

48 ted with significantly reduced risk of major cardiovascular events.

49 ession, and violence), and increased risk of cardiovascular events.

50 to assess the incidence rate of LVNC-related cardiovascular events.

51 he inpatient management of adults with acute cardiovascular events.

52 ngly associated with increased mortality and cardiovascular events.

53 sociated with an increased incidence of late cardiovascular events.

54 is affects postintervention adverse limb and cardiovascular events.

55 on between slopes and the risks of death and cardiovascular events.

56 dently associated with cardiac mechanics and cardiovascular events.

57 ence in a composite outcome of major adverse cardiovascular events.

58 e 0.73 (95% CI, 0.62-0.84) for major adverse cardiovascular events, 0.92 (95% CI, 0.85-1.00) for majo

59 n reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and

60 death (40.9% versus 54.5%) and major adverse cardiovascular events (47.6% versus 59.5%), but with a l

61 espect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiov

62 s were invasive cancer of any type and major cardiovascular events (a composite of myocardial infarct

63 on between eGFR slopes and risks of death or cardiovascular events, accounting for multiple confounde

64 th early-stage breast cancer who experienced cardiovascular events after cancer diagnosis had increas

65 ed survival and greater freedom from adverse cardiovascular events after complete revascularization (

66 after exercise, suggesting a reduced risk of cardiovascular events after exertion.

67 -terminal pro-B-type natriuretic peptide and cardiovascular events after noncardiac surgery: a cohort

68 he association between LDL-C and longer-term cardiovascular events after PCIs.

69 rt study, there was a 3-fold higher risk for cardiovascular events after starting an ICI (hazard rati

70 olic and systolic indices, as well as future cardiovascular events (all P<0.05).

71 pharmacy supply >30 days) and major adverse cardiovascular events (all-cause death, myocardial infar

72 ary widely with the greatest risk for future cardiovascular events among those who develop giant coro

73 e an independent predictor for major adverse cardiovascular events and adverse left ventricular remod

74 e supports a strong link between the risk of cardiovascular events and all-cause mortality with PM(2.

75 CE, is associated with an increased risk for cardiovascular events and all-cause mortality.

76 disease was associated with a lower risk of cardiovascular events and an increased risk of major ble

77 ents about aspirin for primary prevention of cardiovascular events and bleeding.

78 levels, lipoprotein levels, and the risk of cardiovascular events and cancer.

79 as performed on 50 adult patients with acute cardiovascular events and cardiac arrest survivors, test

80 utcomes demonstrated significantly fewer new cardiovascular events and fractures in intervention part

81 th, other cancers, and major adverse events (cardiovascular events and fractures).

82 c inflammation independently predicts future cardiovascular events and is associated with a 2-fold in

83 nular calcification (MAC) is associated with cardiovascular events and mitral valve dysfunction.

84 to investigate the effects of liraglutide on cardiovascular events and mortality in LEADER (Liragluti

85 ase, is associated with an increased risk of cardiovascular events and mortality.

86 ne disease associated with an increased risk cardiovascular events and mortality.

87 provides a simple, novel strategy to predict cardiovascular events and progression in PAD patients.

88 sease (ACHD), the long-term risks of adverse cardiovascular events and relationship with conventional

89 ffects of yoga-based CR (Yoga-CaRe) on major cardiovascular events and self-rated health in a multice

90 ause they decrease the risk of major adverse cardiovascular events and slow progression of diabetic k

91 imed at reducing the risk of atherosclerotic cardiovascular events and their adverse prognostic conse

92 efit for its primary outcome (a composite of cardiovascular events) and all-cause mortality on August

93 c plaques are destabilizing, predict adverse cardiovascular events, and are associated with increased

94 d 2842 controls matched by age, a history of cardiovascular events, and cancer type.

95 nt 5-year all-cause mortality, major adverse cardiovascular events, and initiation of kidney replacem

96 ucing SSB consumption on diabetes incidence, cardiovascular events, and mortality in Argentina during

97 substantial decrease in diabetes incidence, cardiovascular events, and mortality in Argentina.

98 ition, serious adverse events, major adverse cardiovascular events, and other adverse events.

99 ial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboemb

100 hronic kidney disease and/or atherosclerotic cardiovascular events, and the risk of death.

101 Cardiovascular events are among the leading cause of mor

102 indicate that these daily rhythms in adverse cardiovascular events are at least partially under the c

103 The risks of cardiovascular events are frequently underestimated and

104 echanisms through which NSAIDs cause adverse cardiovascular events are not entirely understood.

105 Cardiac dysfunction and cardiovascular events are prevalent among patients with

106 Arterial cardiovascular events are the leading cause of death in

107 id (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy i

108 lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than

109 The increased risk of cardiovascular events associated with aromatase inhibito

110 chronic conditions, to protect against acute cardiovascular events associated with influenza.

111 We aimed to quantify the risk of adverse cardiovascular events associated with lower-complexity A

112 and lipid levels were effective in reducing cardiovascular events, blood pressure, low-density lipop

113 h PAD are at risk for not only major adverse cardiovascular events but also major adverse limb events

114 ow-dose aspirin (100 mg/d) does not decrease cardiovascular events but does increase surgical bleedin

115 bsolute risks of mortality and major adverse cardiovascular events, but also with a lower absolute ri

116 in patients with a low risk of major adverse cardiovascular events, but may be useful in patients wit

117 ffective strategies for reducing the risk of cardiovascular events, but multiple studies have reporte

118 .69-0.76] for CABG) and 5-year major adverse cardiovascular events (C-index=0.65 [0.61-0.69] for PCI

119 ting 10-year deaths and 5-year major adverse cardiovascular events can help to identify individuals w

120 fety endpoint was freedom from major adverse cardiovascular events (cardiac death, myocardial infarct

121 ssociated with decreased risk of significant cardiovascular events compared to nonsurgical controls.

122 icipants in the minimal care group had major cardiovascular events compared with 202 (5.9%) of 3421 p

123 similar relative reduction in major adverse cardiovascular events compared with aspirin in participa

124 vascular disease and risk stratification for cardiovascular events constitute an important part of th

125 rly kidney function, and impact of long-term cardiovascular events (CVE) after liver transplantation

126 lysis, SAF is an independent risk factor for cardiovascular events (CVEs) and all-cause mortality (AC

127 ily history of atrial fibrillation (AF) with cardiovascular events (CVEs), major adverse cardiac even

128 ostic value of QT dynamics was evaluated for cardiovascular events (death or hospitalization) and all

129 Secondary outcomes included major adverse cardiovascular events (death, myocardial infarction, str

130 s complications, lower risk of major adverse cardiovascular events, death, new MI, and new onset hear

131 The risk of composite cardiovascular events decreased in the surgical group [h

132 to predict the 5-year risk of major adverse cardiovascular events (defined as a composite of all-cau

133 ough in-hospital mortality and major adverse cardiovascular events did not differ by race/ethnicity a

134 d an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up.

135 luenza may contribute to the burden of acute cardiovascular events during annual influenza epidemics.

136 risk (>=1%) for perioperative major adverse cardiovascular events during the surgical hospital admis

137 e the influence of LDL-C on the incidence of cardiovascular events either following a coronary revasc

138 e considered as a natural screening tool for cardiovascular events, enabling cardiovascular risk prev

139 resulting in increased risk of major adverse cardiovascular events, especially after percutaneous cor

140 esterol (LDL-C) is associated with increased cardiovascular events, especially in high-risk populatio

141 ents of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction,

142 e was projected to avert 40-54 major adverse cardiovascular events for every 1000 patients treated fo

143 ase-crossover, there was also an increase in cardiovascular events from 1.37 to 6.55 per 100 person-y

144 CH was associated with an increased risk for cardiovascular events (hazard ratio [HR], 1.36 [95% CI,

145 nstriction continued to show higher risk for cardiovascular events [hazard ratio: 4.1; 95% confidence

146 Atherosclerosis progression predicts cardiovascular events; however, progression of multiterr

147 FA) has been associated with reduced risk of cardiovascular events; however, this has not been confir

148 progressively increasing risks of death and cardiovascular events; however, we found no increased ri

149 ociated with post-LT survival (P = 0.25) nor cardiovascular events (HR, 1.08; 95% CI, 0.73-1.59; P =

150 .39; for a slope 1 SD below the average) and cardiovascular events (HR, 1.19; 95% CI, 1.03 to 1.38).

151 es that included stroke in the definition of cardiovascular events (HR, 1.26 [CI, 1.00 to 1.54]).

152 o an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls

153 mg/dL in terms of reducing the risk of major cardiovascular events in 2860 patients with ischemic str

154 Genetic risk scores were not associated with cardiovascular events in 357 882 unrelated individuals f

155 d remnant cholesterol (remnant-C) with major cardiovascular events in a cohort of older individuals a

156 entify individuals at risk for major adverse cardiovascular events in a community-based cohort.

157 associated with increased risks of death and cardiovascular events in a U-shaped fashion.

158 tive myocardial infarction and major adverse cardiovascular events in adults aged 75 years or older (

159 LAEDVI is a strong predictor of cardiovascular events in ambulatory patients with stable

160 n did not significantly reduce major adverse cardiovascular events in any voucher use likelihood grou

161 lcium (CAC) to predict risk of major adverse cardiovascular events in asymptomatic patients is accept

162 While elevated risk and incidence of cardiovascular events in breast cancer is well establish

163 tty acid formulation to reduce major adverse cardiovascular events in high-risk patients.

164 been shown to lead to a marked reduction in cardiovascular events in humans.

165 ociated with increased risk of major adverse cardiovascular events in individuals <55 years of age (h

166 re to examine endothelial function) predicts cardiovascular events in PAD patients.

167 agents vorapaxar and prasugrel for reducing cardiovascular events in patients at high cardiovascular

168 t as a strategy to reduce risk for recurrent cardiovascular events in patients who have had recent is

169 icagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary sy

170 OSA has not been shown to increase recurrent cardiovascular events in patients with acute coronary sy

171 and secondary prevention of atherosclerotic cardiovascular events in patients with CAD and DM.

172 apies aimed at further reducing the risks of cardiovascular events in patients with chronic - but not

173 -stimulating agents (ESAs) may contribute to cardiovascular events in patients with CKD and anemia.

174 hibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chr

175 ssociations between LGE presence and adverse cardiovascular events in patients with dilated cardiomyo

176 (a) are associated with an increased risk of cardiovascular events in patients with established cardi

177 e consistently shown safety and reduction in cardiovascular events in patients with established CVD.

178 ss and sleeve gastrectomy) and major adverse cardiovascular events in patients with previous myocardi

179 es Mellitus), PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attac

180 ab significantly reduced the total number of cardiovascular events in patients with prior MI and evid

181 ory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial

182 and have also been shown to reduce recurrent cardiovascular events in patients with stable coronary d

183 is associated with increased risk of future cardiovascular events in patients with subclinical, nono

184 RNC may translate into a reduction in future cardiovascular events in psoriasis.

185 wledge gap exists regarding their effects on cardiovascular events in real-world populations.

186 tory effects and a reduced risk of recurrent cardiovascular events in stable patients with previous m

187 s common but not associated with survival or cardiovascular events in this study.

188 ney disease on abnormal cardiac function and cardiovascular events in those without overt coronary ar

189 age-adjusted incidence rate of major adverse cardiovascular events, in contrast to 13% in individuals

190 Longer-term (up to 4 years) major adverse cardiovascular events, including all-cause death, myocar

191 effect of canakinumab on the total number of cardiovascular events, including recurrent events collec

192 the use of aspirin for primary prevention of cardiovascular events is a suitable and laudable approac

193 sed medication persistence and major adverse cardiovascular events is unknown.

194 ll-cause death and major adverse cardiac and cardiovascular events (MACCE) as outcomes of interest.

195 All-cause mortality, major adverse cardiovascular events (MACE) (cardiovascular death, myoc

196 s were: 1) first occurrence of major adverse cardiovascular events (MACE) (composite of all-cause mor

197 The majority of stent-related major adverse cardiovascular events (MACE) after percutaneous coronary

198 luence on the effect of fenofibrate on major cardiovascular events (MACE) among 3,065 self-reported w

199 ), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OU

200 en shown to reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone

201 se (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those without

202 primary composite endpoint of major adverse cardiovascular events (MACE) comprised coronary heart di

203 al stress is a risk factor for major adverse cardiovascular events (MACE) in individuals with coronar

204 ease (CVD) outcomes as well as major adverse cardiovascular events (MACE) in the Diabetes Control and

205 Predefined end points were major adverse cardiovascular events (MACE) within 12 months.

206 ated with a lower incidence of major adverse cardiovascular events (MACE), all-cause mortality, and r

207 cts of their unbalanced use on major adverse cardiovascular events (MACE), defined as cardiovascular

208 mary outcome was the report of major adverse cardiovascular events (MACE), defined as incident myocar

209 followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular

210 ess MBF and MPR with death and major adverse cardiovascular events (MACE), including myocardial infar

211 Major adverse cardiovascular events (MACE), which included death, stro

212 required to see a reduction in major adverse cardiovascular events (MACE).

213 (Hounsfield units) may predict major adverse cardiovascular events (MACE).

214 ty [AmygA]) and higher risk of major adverse cardiovascular events (MACE).

215 LDL-C independently predicted major adverse cardiovascular events (MACE).

216 ated with a lower incidence of major adverse cardiovascular events (MACE, adjusted HR 0.80, 95% CI 0.

217 Rates of 5-year major adverse cardiovascular events (MACE; a composite of cardiac deat

218 bo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular death, s

219 ition risk and all-cause mortality and major cardiovascular events (MACEs) (cardiovascular mortality,

220 olic blood pressure (SBP) with major adverse cardiovascular events (MACEs) and major adverse limb eve

221 lipid profile and searched for major adverse cardiovascular events (MACEs) in the high-risk primary p

222 Major adverse cardiovascular events (MACEs) were analyzed.

223 y endpoints included composite major adverse cardiovascular events (MACEs), all-cause mortality, and

224 ed the rates of the composite of all serious cardiovascular events (MI, stroke, coronary revasculariz

225 Cardiovascular events, mortality, subjective well-being,

226 y outcome was a composite of atherosclerotic cardiovascular events (myocardial infarction, coronary r

227 y and the secondary outcome of major adverse cardiovascular events (myocardial infarction, heart fail

228 lar disease (CVD) and incident major adverse cardiovascular events (myocardial infarction, stroke, or

229 Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, stroke, or

230 ary endpoint was the development of specific cardiovascular events - myocardial infarction (MI), and

231 omposite events [deaths (n = 8,662) or major cardiovascular events (n = 5,979)].

232 ome for this review was a composite of fatal cardiovascular events, nonfatal myocardial infarction, a

233 3.7 years of follow-up, 3,417 total serious cardiovascular events occurred in 2,003 individuals amon

234 Major adverse cardiovascular events occurred in 61 of 1591 patients (3

235 03], P<0.001), and in-hospital major adverse cardiovascular events (odds ratio, 1.8 [95% CI, 1.42-2.1

236 d to assess noninferiority for major adverse cardiovascular events of the BioFreedom stent compared w

237 rategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparis

238 ative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a med

239 intervention and usual care groups included cardiovascular events or hospitalizations (4 [2.0%] vs 7

240 No trials were powered to assess cardiovascular events or prostate cancer, and trials oft

241 me until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months.

242 e) and pathophysiology (eg, onset of adverse cardiovascular events) oscillate during the 24-hour day.

243 (0.90, 0.80-1.03) or for the expanded major cardiovascular events outcome (0.95, 0.89-1.01).

244 The primary major adverse cardiovascular events outcome comprised cardiovascular d

245 The hazard ratios for composite cardiovascular events outcome in propensity score-matche

246 The primary composite major adverse cardiovascular events outcome was time to first occurren

247 o important reasons: the continuing risks of cardiovascular events over the longer term and the diver

248 ll led to a steady increase in major adverse cardiovascular events over time.

249 d, cause of arterial hypertension and excess cardiovascular events, particularly atrial fibrillation.

250 entions were associated with a lower risk of cardiovascular events (pooled relative risk, 0.80 [95% C

251 independently influenced the risk of adverse cardiovascular events, regardless of the definition of h

252 mplexity ACHD had a higher burden of adverse cardiovascular events relative to the general population

253 baseline cardiovascular risk and subsequent cardiovascular events requires further investigation.

254 The primary end point was cardiovascular events; secondary end points were all-cau

255 tidase 4 inhibitors have variable effects on cardiovascular events, sodium glucose cotransporter 2 in

256 hat begin with lifestyle choices and lead to cardiovascular events span multiple organ systems, inclu

257 on as well as ischemic stroke, major adverse cardiovascular events, splanchnic vein thrombosis, and b

258 mary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack

259 fic-related noise and the incidence of major cardiovascular events such as acute myocardial infarctio

260 iovascular disease (CVD), resulting in acute cardiovascular events, such as heart attack and stroke.

261 and COVID-19 infection and the risk of acute cardiovascular events, summarize the data to date on the

262 ssures (BP) are more predictive of long-term cardiovascular events than clinic BP.

263 ill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participant

264 such, they are more prone to atherosclerotic cardiovascular events than patients without DM, both bef

265 reactive protein and did not result in fewer cardiovascular events than placebo.

266 sulted in lower risks of CKD progression and cardiovascular events than placebo.

267 pass was associated with a lower risk of all cardiovascular events than sleeve gastrectomy.

268 te benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients wit

269 an be a potential modifiable risk factor for cardiovascular events, that is, surgical technique, type

270 associated with an increased risk of adverse cardiovascular events, the accurate incidence of cardiov

271 is often limited by the unpredictability of cardiovascular events, the intermittent nature of ambula

272 DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarct

273 1, with stratification according to previous cardiovascular events) to continue allopurinol (at the o

274 anoma skin cancer, other malignancies, major cardiovascular events, venous thromboembolism, and morta

275 the patients, the incidence of major adverse cardiovascular events was 2.9% in the relugolix group an

276 int of the 30-day freedom from major adverse cardiovascular events was 92.2%; the lower bound of the

277 year cumulative probability of major adverse cardiovascular events was lower in patients undergoing m

278 Overall, no risk reduction on major adverse cardiovascular events was observed (HR: 0.91 [95% CI 0.8

279 s with chronic coronary disease, the risk of cardiovascular events was significantly lower among thos

280 y indexes of neutrophilia with major adverse cardiovascular events was studied in a cohort of patient

281 The primary end point, major adverse cardiovascular events, was defined as the composite of c

282 e adjusted subdistribution hazard ratios for cardiovascular events were 1.17 (95% confidence interval

283 rpes zoster infection, malignancy, and major cardiovascular events were 2.81 per 100 person-years, 2.

284 After a median 3.2 years, the rates of cardiovascular events were 55.2/1,000 person-years for t

285 Acute cardiovascular events were ascertained using discharge c

286 liraglutide versus placebo on major adverse cardiovascular events were consistent in patients with (

287 Cardiovascular events were higher after initiation of IC

288 Acute cardiovascular events were identified by ICD discharge c

289 Longer-term major adverse cardiovascular events were lower in the CAC-absent (2.4%

290 Major cardiovascular events were more common among those with

291 The largest reductions in diabetes and cardiovascular events were observed in the youngest age

292 iations between eGFR, cardiac mechanics, and cardiovascular events were partly mediated via CFR.

293 ociated with greatest risk for major adverse cardiovascular events, while prior peripheral revascular

294 symptoms, and individualizing their risk of cardiovascular events with a special consideration for n

295 exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes

296 he absolute risk reduction for major adverse cardiovascular events with alirocumab was numerically gr

297 This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Interventio

298 REDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention

299 a-3 fatty acids hold the potential to reduce cardiovascular events with limited adverse effects in th

300 nakinumab reduced the rates of total serious cardiovascular events, with rates per 100 person-years i